USA - NASDAQ:AERI - US00771V1089 - Common Stock
ChartMill assigns a Buy % Consensus number of 71% to AERI. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-08-29 | Citigroup | Downgrade | Buy -> Neutral |
| 2022-08-24 | Truist Securities | Downgrade | Buy -> Hold |
| 2022-08-24 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2022-08-23 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2022-08-23 | Needham | Downgrade | Buy -> Hold |
| 2022-08-23 | Stifel | Downgrade | Buy -> Hold |
| 2022-05-09 | HC Wainwright & Co. | Maintains | Buy |
| 2022-02-25 | Needham | Maintains | Buy |
| 2021-11-05 | Needham | Maintains | Buy |
| 2021-08-05 | Needham | Maintains | Buy |
14 analysts have analysed AERI and the average price target is 15.63 USD. This implies a price increase of 2.48% is expected in the next year compared to the current price of 15.25.
The consensus rating for AERIE PHARMACEUTICALS INC (AERI) is 71.4286 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering AERIE PHARMACEUTICALS INC (AERI) is 14.